AnaptysBio Inc
$ 55.11
-0.54%
25 Feb - close price
- Market Cap 1,549,984,000 USD
- Current Price $ 55.11
- High / Low $ 57.22 / 54.79
- Stock P/E N/A
- Book Value -1.07
- EPS -2.82
- Next Earning Report 2026-02-26
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.04 %
- ROE -3.08 %
- 52 Week High 57.73
- 52 Week Low 13.99
About
AnaptysBio, Inc., a clinical-stage biotechnology company, is dedicated to developing therapeutic product candidates for inflammation and immuno-oncology indications. The company is headquartered in San Diego, California.
Analyst Target Price
$67.92
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-04 | 2025-08-07 | 2025-05-07 | 2025-03-10 | 2024-11-08 | 2024-08-05 | 2024-05-09 | 2024-03-11 | 2023-11-02 | 2023-08-07 | 2023-05-11 | 2023-03-01 |
| Reported EPS | 0.52 | -1.34 | -1.28 | -0.72 | -1.14 | -1.71 | -1.64 | -1.59 | -1.41 | -1.5 | -1.58 | -0.93 |
| Estimated EPS | -1.4 | -1.52 | -1.56 | -1.7049 | -1.65 | -0.99 | -1.57 | -1.6 | -1.79 | -1.7 | -1.05 | -0.96 |
| Surprise | 1.92 | 0.18 | 0.28 | 0.9849 | 0.51 | -0.72 | -0.07 | 0.01 | 0.38 | 0.2 | -0.53 | 0.03 |
| Surprise Percentage | 137.1429% | 11.8421% | 17.9487% | 57.7688% | 30.9091% | -72.7273% | -4.4586% | 0.625% | 21.2291% | 11.7647% | -50.4762% | 3.125% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-02-26 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | 0.89 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ANAB
2026-02-24 17:52:00
AnaptysBio (ANAB) stock reached a new 52-week high at $57.62, showcasing a 215.6% increase over the past year. This surge is attributed to investor confidence and positive market sentiment, despite InvestingPro data suggesting the stock might be overvalued. The company is actively involved in litigation with GSK and recently received a boost from a $500 million funding agreement between Royalty Pharma and Teva.
2026-02-23 05:49:31
The article analyzes Anaptysbio Inc. (ANAB) through AI models, identifying a near-term neutral sentiment amidst mid- and long-term strength. It highlights an exceptional risk-reward short setup and provides institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis. The piece suggests that ANAB is testing resistance and outlines specific entry, target, and stop-loss points for various strategies.
2026-02-21 13:37:04
Skandinaviska Enskilda Banken AB publ significantly increased its stake in AnaptysBio, Inc. (NASDAQ:ANAB) by 333.1% in Q3, now holding 145,191 shares valued at approximately $4.45 million. Other institutional investors like Assenagon Asset Management S.A. also dramatically boosted their holdings, indicating strong institutional accumulation. AnaptysBio's board has authorized a $100 million share buyback, and analysts maintain a "Moderate Buy" rating with an average target price of $66.89 against a current trading price near $54.
2026-02-20 19:49:21
AnaptysBio, Inc. (ANAB), a clinical-stage biotechnology company, shows a 22.46% potential upside with strong buy ratings from analysts, despite reporting negative EPS and free cash flow. The company's stock is performing well, trading at the upper end of its 52-week range, largely due to its promising immunology therapeutics pipeline, including Imsidolimab in Phase 3 development. While AnaptysBio presents a speculative investment due to its pre-revenue status and operational losses, its strategic collaborations and positive technical indicators suggest potential for significant gains for risk-tolerant investors.
2026-02-19 10:57:24
GSA Capital Partners LLP significantly reduced its holdings in AnaptysBio, Inc. (NASDAQ:ANAB) by 46.6% in the third quarter, while several other institutional investors, such as Assenagon Asset Management S.A., 683 Capital Management LLC, Soleus Capital Management L.P., JPMorgan Chase & Co., and Federated Hermes Inc., substantially increased their positions. AnaptysBio also announced a $100 million share repurchase program, indicating management's belief that the stock may be undervalued. Insider selling by Eric J. Loumeau and CEO Daniel Faga was also reported, alongside various analyst ratings and price target adjustments.
2026-02-19 08:57:24
AnaptysBio (ANAB) is expected to release its Q4 2025 earnings before market open on Thursday, February 26th, with analysts projecting $0.89 earnings per share. Wall Street maintains a "Moderate Buy" consensus rating with a target price of $66.89, supported by recent price target increases from firms like Wells Fargo and Barclays. The company has also initiated a $100 million stock repurchase program, indicating management's belief that the stock may be undervalued, while insider selling has been noted by the CEO and another insider.
